Abbott Launches Trial Of First-Of-A-Kind Resorbable Scaffold For Critical Limb Ischemia
Executive Summary
The Esprit BTK everolimus-eluting resorbable scaffold is designed to treat arteries below the knee. No stents or drug-coated balloons are currently FDA-approved for that indication.
You may also be interested in...
News We're Watching: TCT Yields More Encouraging Results For TAVR; HeartPoint Resets Trial Plans, Butterfly Tries Brain-Interface Tech
Clinical trial results announced at the Transcatheter Therapeutics conference in San Francisco headlined the medtech research and development news last week. Noteworthy "commercial" developments in late October include iCad’s decision to sell its Xoft brachytherapy business to Elekta and Butterfly Network's plans to work with Forest Neurotech on brain-computer interfaces.
Exec Chat: Abbott Invests In Outreach To Underrepresented Populations
Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott’s vascular device business, talked to Medtech Insight about her company’s ongoing efforts to diversify patient enrollment in clinical trials by communicating more effectively and compassionately with people in traditionally underrepresented demographic groups.
Abbott Wants To Expand Clinical Trial Access By Diversifying Investigator Community
The company’s plan to reduce barriers to clinical trial participation for underrepresented groups includes the creation of nearly 300 new scholarships at medical schools of historically black colleges and universities and minority nursing associations.